FDA Schedules Joint Meeting to Discuss Birth Control Pill Clot Risk
The FDA has scheduled a joint meeting with the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the risks of the drospirenone-containing birth control pills.
The US FDA said in a safety announcement on Monday that preliminary results of a study that it funded, involving 800,000 women, suggested an approximately 1.5-fold increase in the risk of blood clots for women who use the drospirenone-containing birth control pills compared with users of other hormonal contraceptives.
The FDA has scheduled a joint meeting with the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on 8 December to discuss the risks and benefits of the pills.
The agency has completed its review of two studies evaluating the risk of blood clots in women, but has not reached a conclusion yet.
Related News
-
News CPHI North America Lookahead: Facilitating ‘meaningful conversations’ on needs and solutions
CPHI NA takes place as a SMART event this year, with online learning and networking from May 9-27 and an in-person event from May 17-19 in Philadelphia, PA. -
News Early development demand continues to boost prospects for smaller CDMOs: CPHI Worldwide panel
The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market -
News CPHI Worldwide is back, and this time it’s hybrid
A new in-person and online edition of CPHI Worldwide, transforming your event experience. -
News 5 Highlights from the Pharmapack Europe Content Programme
Pharmapack Europe is back! Join us online from 27 September as we kick off our two-week long content programme, a great precursor to the in-person event from 13-14 October at the Paris Expo Porte de Versailles. -
News Finding the right experts and collaborating at speed essential to COVID-19 vaccine rollout, says CPHI panel
CPHI Discover webinar examines the progress made so far in terms of vaccine distribution to the global population as well as anticipating future challenges -
News UPDATED: The CPHI Discover Blog
Bookmark this page for regular updates on the rich variety of content coming your way via CPHI Discover, pharma’s largest ever virtual gathering, over the course of our three-day agenda -
News COVID-19 has exacerbated contract manufacturing challenges but industry continues to respond well to crisis: experts
Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told -
News APIs, excipients and formulation: the bedrock of medical innovation
Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in APIs, Ingredients & Formulation
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance